opdivo_1_1

BMS’ Opdivo falls short at Phase 3 in glioblastoma multiforme

pharmafile | September 5, 2019 | News story | Research and Development BMS, glioblastoma multiforme, opdivo, pharma 

Bristol-Myers Squibb has revealed that its blockbuster immunotherapy Opdivo (nivolumab) fell short of its primary Phase 3 endpoint in the treatment of newly diagnosed glioblastoma multiforme (GBM) when combined with the current standard of care, temozolomide and radiation therapy).

The manufacturer revealed that its combo failed to show adequate benefit in progression-free survival (PFS) in patients with GBM that is O6-methylguanine-DNA methyltransferase (MGMT)-methylated, compared to standard of care alone.

Despite the failure, BMS confirmed that the trial would continue under recommendation from the data monitoring committee in order to allow data to mature and meet its other primary endpoint of overall survival.

“Though CheckMate -548 did not show statistically significant improvement in progression-free survival, we are continuing to evaluate the benefit the addition of Opdivo to the standard of care treatment regimen may bring to patients suffering from GBM, an extremely aggressive and difficult disease to treat. We look forward to seeing the overall survival data when they are available,” commented Dr Fouad Namouni, Head of Oncology Development at Bristol-Myers Squibb. “We are grateful to the patients, caregivers and investigators participating in this trial who make this research possible.”

Advertisement

Matt Fellows

Related Content

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

blood_test

Johnson & Johnson announces successful results from trial for myeloma treatment

Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …

Bristol Myers Squibb receives positive CHMP opinion for Opdivo treatment

Bristol Myers Squibb (BMS) has received a positive opinion from the Committee for Medicinal Products …

The Gateway to Local Adoption Series

Latest content